CCL2 and Alzheimer disease: Pioglitazone and rosiglitazone also lower IL-6 and TNF-α cytokines in STZ-induced AD [126, 291, 292], while T3D-959 decreases several pro-inflammatory cytokines (IL-12, IFN-γ, macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and RANTES), and increases anti-inflammatory cytokines (IL-10, IL-1α and IL-7) in the temporal lobe from STZ-treated rats [124].